Name of the Procedure:

Injection of pegfilgrastim-cbqv, biosimilar, commonly known as Udenyca.

Summary

The procedure involves administering an injection of pegfilgrastim-cbqv, a biosimilar to Udenyca, which is a medication used to help stimulate the production of white blood cells in patients undergoing chemotherapy.

Purpose

Pegfilgrastim-cbqv is used to reduce the risk of infection in patients receiving chemotherapy that may cause a severe decrease in white blood cells (neutropenia). The goal is to aid the bone marrow in producing more white blood cells, thereby helping to fight infections and support overall immune function.

Indications

• Low white blood cell count (neutropenia) due to chemotherapy.
• Increased risk of infection due to low white blood cells.
• Patients undergoing specific types of chemotherapy that are known to cause neutropenia.

Preparation

• Patients should inform their healthcare provider about any other medications they are taking.
• No specific fasting or dietary restrictions are generally required.
• Blood tests may be performed to check current white blood cell levels before the injection.

Procedure Description

1. The healthcare provider prepares the injection site by cleaning it with an antiseptic.
2. Pegfilgrastim-cbqv is administered as a subcutaneous injection, typically in the upper arm, thigh, or abdomen.
3. The injection process takes just a few minutes.
4. The healthcare provider monitors the patient for any immediate reactions post-injection.

Duration

The injection itself takes a few minutes, but the entire appointment may take 15-30 minutes to allow for preparation and observation.

Setting

This procedure is usually performed in an outpatient clinic, hospital, or doctor's office.

Personnel

• Registered Nurse (RN) or Licensed Practical Nurse (LPN) usually administers the injection.
• Physician or Oncologist oversees the treatment plan.

Risks and Complications

• Common: Injection site reactions (redness, swelling, pain), bone pain, muscle pain.
• Rare: Allergic reactions, spleen rupture, acute respiratory distress syndrome (ARDS).

Benefits

• Reduces the duration of severe neutropenia and the risk of infection.
• Allows patients to continue with their chemotherapy schedule without delays due to low white blood cell counts.
• Benefits are typically seen within a few days to a week after administration.

Recovery

• Patients can return to normal activities shortly after the injection.
• Follow-up blood tests may be required to monitor white blood cell counts.
• Patients should report any severe side effects or symptoms to their healthcare provider immediately.

Alternatives

• Other growth factors such as filgrastim (Neupogen) may be used.
• Antibiotic prophylaxis to manage infection risk.
• Supportive treatments such as dose modifications or delays in chemotherapy.

Patient Experience

• Patients might experience mild discomfort during the injection and potential soreness at the injection site afterward.
• Bone pain is a common side effect, which can be managed with over-the-counter pain relievers or medications prescribed by the healthcare provider.
• Overall, the procedure is typically well-tolerated, and healthcare providers take measures to maintain patient comfort throughout.